Skip to main content

Table 2 Characteristics of the ‘Improving Secondary Prophylaxis’ stepped-wedge trial

From: Improving delivery of secondary prophylaxis for rheumatic heart disease in remote Indigenous communities: study protocol for a stepped-wedge randomised trial

Term/Trial characteristic Definition
Unit Aboriginal health centres
Cluster Pairs of health centres
Individuals People with ARF/RHD who require secondary prophylaxis with penicillin, whose primary health centre is enrolled in the study
Timing of start of exposure Groups of individuals (all individuals managed by a given community clinic) are first exposed at one of a number of discrete time points
Duration of exposure Fixed length: 15 months per clinic
Measurement Repeated measurements from individuals: record of every penicillin injection received, as documented in the ARF/RHD Register
Duration of trial 3.5 years
Number of clinics per cluster 2
Total number of clusters 5
Pre-roll out period 11 to 25 months
Roll out period 15 months
Post-rollout period 3 to 15 months
  1. ARF acute rheumatic fever, RHD rheumatic heart disease